Human Immune System Shapes Skin Microbiome
News Oct 31, 2013
In a study published online in Genome Research, researchers have explored the microbes living on the skin of patients with primary immunodeficiencies with eczema-like skin conditions.
The human body contains many microbes, some of which are necessary for healthy bodily functions such as digestion. Others, such as some microbes living on our skin, may be pathogenic. Previous studies investigated how these microbes educate and shape the human immune system. There is little known, however, if the immune system influences the types of microbes that live on the skin and thus potentially prevents disease. "In addition to questions about how microbes affect the human host, there is an interest in understanding how the human host affects the microbes that make our skin their home," said Heidi Kong of the National Cancer Institute (NCI) and co-senior author of the study.
To study this, the authors enlisted patients with reduced immune function as a result of rare genetic defects. Despite the diversity in disease-causing mutations in the patients, all patients shared an eczema-like skin condition. The scientists identified the microbes on the patients' skin by sequencing microbial DNA from skin swabs. The immunodeficient patients had types of bacteria and fungi on their skin not found on healthy individuals, suggesting the patients' skin was more permissive to microbe growth. "Our findings suggest that the human body, including our immune systems, constrains and potentially selects which bacteria and fungi can inhabit skin," said Kong.
Interestingly, the skin sites specifically prone to disease showed significant differences in microbial diversity, or the number of different types of microbes present, in immundeficient patients.
The skin at the elbow crease, for instance, had fewer types of microbes than found on healthy individuals, while skin behind the ear had more types of microbes. The authors suggest that an imbalance in microbial diversity at a given site may contribute to disease. In addition, "the communities of bacteria and fungi on the skin of primary immunodeficiency patients are more likely to change over time," said co-senior author Julie Segre, of the National Human Genome Research Institute (NHGRI).
Immunodeficient patients overall had much more similar microbial communities across their entire bodies, which are usually distinct in healthy individuals. The authors suggest that by correcting the diversity of microbes on the skin, not just targeting pathogenic ones, may aid in the treatment of disease.
Although the individuals in this study have rare genetic disorders, this research may have implications for patients with temporary impairments in immune function, such as cancer patients and transplant recipients, and may inform the use of preventative antibiotics that are routinely given to these patients.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.